Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature

Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature

Metastatic colorectal cancer (mCRC) has a poor prognosis. Combining chemotherapy with targeted therapy constitutes a basic form of mCRC treatment. Immune checkpoint inhibitors have been recommended for microsatellite instability mCRC, while most patients harboring microsatellite stability (MSS) or p...

Full description

Bibliographic Details
Main Authors: Minghan Song, Xianrong Zeng, Qian Wu, Jie Huang, Jiayi Dong, Lijuan Shao, Zihao Sun, Yiguang Lin, Size Chen
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Life
Subjects:
colorectal cancer
immunotherapy
PARP inhibitor
BRCA2 mutation
microsatellite stability
case report
Online Access:https://www.mdpi.com/2075-1729/13/5/1183

Internet

https://www.mdpi.com/2075-1729/13/5/1183

Similar Items